Ferguson COO Thees sells $127,125 of FERG stock

Newport News, VA – William T. Thees Jr., Chief Operating Officer of Ferguson Enterprises Inc. (NYSE:FERG), recently sold company stock totaling $127,125. The transactions occurred on October 14 and October 15, 2026. The stock currently trades at $231.61, with the company carrying a market capitalization of $44.25 billion. According to InvestingPro analysis, Ferguson appears slightly overvalued at current levels, placing it among stocks on the Most Overvalued list.

Mr. Thees disposed of a total of 570 common shares at prices ranging from $220.63 to $224.5 per share. These sales were carried out under a Rule 10b5-1 trading plan, which was established on May 27, 2026.

Additionally, Mr. Thees was involved in other transactions during the period. He disposed of 384 common shares to cover tax obligations, with prices for these dispositions ranging between $222.86 and $222.94, totaling $85,601.

He also acquired 19 common shares at a price of $0. These shares represent dividend equivalents received upon the vesting of Restricted Stock Units.

Following these reported transactions, Mr. Thees directly holds 31,745 shares of Ferguson Enterprises Inc. common stock. For deeper insights into Ferguson’s valuation and financial health, investors can access the comprehensive Pro Research Report, available for this and 1,400+ other US equities on InvestingPro.

In other recent news, Ferguson Enterprises reported its fiscal second-quarter 2026 results, showing a 4.6% increase in net sales from the previous year, reaching $8.8 billion. Despite the revenue growth, the company’s diluted earnings per share were significantly lower than expected at $0.04, compared to the $2.94 anticipated by analysts. Additionally, Ferguson has lifted its outlook for future performance, indicating optimism in its operating trends. In analyst updates, Jefferies resumed coverage on Ferguson Enterprises with a buy rating, setting a price target of $295. Bernstein SocGen Group also raised its price target for Ferguson to $325, citing reaccelerating non-residential growth and improving momentum as the company approaches fiscal 2027. Meanwhile, Wells Fargo included Axsome Therapeutics in its list of overweight tactical ideas, expecting growth in Auvelity prescriptions to enhance its commercial potential. These recent developments highlight the dynamic landscape for investors considering these companies.